Eli Lilly and Company (NYSE:LLY) is Cardinal Capital Management’s 5th Largest Position

Cardinal Capital Management raised its holdings in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 0.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,267 shares of the company’s stock after buying an additional 223 shares during the period. Eli Lilly and comprises approximately 2.3% of Cardinal Capital Management’s portfolio, making the stock its 5th largest position. Cardinal Capital Management’s holdings in Eli Lilly and were worth $11,531,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Marietta Wealth Management LLC boosted its holdings in shares of Eli Lilly and by 30.3% during the first quarter. Marietta Wealth Management LLC now owns 16,278 shares of the company’s stock worth $4,662,000 after purchasing an additional 3,787 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in shares of Eli Lilly and by 10.3% during the fourth quarter. Integrated Wealth Concepts LLC now owns 17,255 shares of the company’s stock worth $4,766,000 after purchasing an additional 1,613 shares during the period. Central Bank & Trust Co. boosted its holdings in shares of Eli Lilly and by 7.4% during the first quarter. Central Bank & Trust Co. now owns 2,705 shares of the company’s stock worth $775,000 after purchasing an additional 186 shares during the period. Vestmark Advisory Solutions Inc. boosted its holdings in shares of Eli Lilly and by 3.1% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 12,157 shares of the company’s stock worth $3,358,000 after purchasing an additional 364 shares during the period. Finally, Wedbush Securities Inc. raised its stake in Eli Lilly and by 110.1% in the fourth quarter. Wedbush Securities Inc. now owns 11,235 shares of the company’s stock worth $3,103,000 after buying an additional 5,887 shares in the last quarter. Institutional investors and hedge funds own 82.75% of the company’s stock.

Shares of NYSE:LLY traded down $5.68 during trading on Friday, reaching $318.55. 13,455 shares of the stock traded hands, compared to its average volume of 3,019,638. The stock has a 50-day moving average of $300.45 and a two-hundred day moving average of $278.15. Eli Lilly and Company has a 52-week low of $220.20 and a 52-week high of $330.85. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The stock has a market cap of $302.67 billion, a P/E ratio of 48.03, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The firm had revenue of $7.81 billion for the quarter, compared to analysts’ expectations of $7.29 billion. During the same quarter in the prior year, the company posted $1.87 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 8.27 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Friday, August 12th. Eli Lilly and’s dividend payout ratio is presently 58.07%.

A number of equities analysts recently issued reports on LLY shares. StockNews.com raised shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research note on Friday. SVB Leerink started coverage on shares of Eli Lilly and in a research note on Monday, May 23rd. They issued an “outperform” rating and a $341.00 price target for the company. Bank of America increased their price target on shares of Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Finally, Morgan Stanley raised their target price on shares of Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $311.65.

In other news, major shareholder Lilly Endowment Inc sold 39,393 shares of Eli Lilly and stock in a transaction on Monday, April 4th. The shares were sold at an average price of $293.15, for a total transaction of $11,548,057.95. Following the transaction, the insider now owns 105,835,661 shares in the company, valued at approximately $31,025,724,022.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $313.44, for a total transaction of $313,440.00. Following the sale, the chief accounting officer now owns 6,274 shares in the company, valued at $1,966,522.56. The disclosure for this sale can be found here. Insiders have sold a total of 1,140,073 shares of company stock worth $355,891,104 in the last quarter. Corporate insiders own 0.12% of the company’s stock.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.